Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Back to Search
Print
Bookmark Trial

NCT01994889

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
The Kirklin Clinic
Birmingham, Alabama, 35249, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Transthyretin (TTR) Amyloid Cardiomyopathy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on x-ray or auscultation, peripheral edema) that required/requires treatment with a diuretic for improvement,

- Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness > 12 mm,

- Presence of amyloid deposits in biopsy tissue and presence of a variant TTR genotype and/or TTR precursor protein identification by immunohistochemistry, scintigraphy or mass spectrometry

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- A New York Heart Association (NYHA) classification of IV.


- Presence of primary (light chain) amyloidosis.


- Prior liver or heart transplantation or implanted cardiac mechanical assist device.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Transthyretin (TTR) Amyloid CardiomyopathySafety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
NCT01994889
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Phoenix, Arizona
  5. Phoenix, Arizona
  6. Scottsdale, Arizona
  7. La Jolla, California
  8. La Jolla, California
  9. La Jolla, California
  10. La Jolla, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. San Francisco, California
  15. Stanford, California
  16. Deerfield Beach, Florida
  17. Miami, Florida
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Oak Lawn, Illinois
  21. New Orleans, Louisiana
  22. Baltimore, Maryland
  23. Baltimore, Maryland
  24. Baltimore, Maryland
  25. Boston, Massachusetts
  26. Boston, Massachusetts
  27. Boston, Massachusetts
  28. Boston, Massachusetts
  29. Ann Arbor, Michigan
  30. Rochester, Minnesota
  31. Rochester, Minnesota
  32. Newark, New Jersey
  33. New York, New York
  34. New York, New York
  35. New York, New York
  36. New York, New York
  37. New York, New York
  38. New York, New York
  39. Durham, North Carolina
  40. Cleveland, Ohio
  41. Portland, Oregon
  42. Portland, Oregon
  43. Portland, Oregon
  44. Philadelphia, Pennsylvania
  45. Nashville, Tennessee
  46. Houston, Texas
  47. Salt Lake City, Utah
  48. Richmond, Virginia
  49. Richmond, Virginia
  50. Seattle, Washington
  51. Leuven,
  52. Rio de Janeiro, RJ
  53. Calgary, Alberta
  54. Toronto, Ontario
  55. Brno,
  56. Brno,
  57. Praha 2,
  58. Praha 2,
  59. Praha 4,
  60. Praha 4,
  61. Clamart,
  62. Creteil,
  63. Heidelberg,
  64. Muenster,
  65. Bologna,
  66. Brescia,
  67. Firenze,
  68. Pavia,
  69. Kurume-shi, Fukuoka
  70. Kumamoto-city, Kumamoto
  71. Nagano,
  72. Groningen,
  73. Majadahonda, Madrid
  74. El Palmar, Murcia
  75. A Coruna,
  76. Skelleftea,
  77. Uppsala,
  78. London,
  79. London,
  80. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Transthyretin (TTR) Amyloid CardiomyopathyLong-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
NCT02791230
  1. Heidelberg,
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Beverly Hills, California
  6. Beverly Hills, California
  7. La Jolla, California
  8. La Jolla, California
  9. Los Angeles, California
  10. San Diego, California
  11. San Diego, California
  12. San Francisco, California
  13. San Francisco, California
  14. San Francisco, California
  15. Stanford, California
  16. Stanford, California
  17. Deerfield Beach, Florida
  18. Miami, Florida
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Chicago, Illinois
  22. Oak Lawn, Illinois
  23. Baltimore, Maryland
  24. Baltimore, Maryland
  25. Boston, Massachusetts
  26. Boston, Massachusetts
  27. Boston, Massachusetts
  28. Ann Arbor, Michigan
  29. Ann Arbor, Michigan
  30. Rochester, Minnesota
  31. Rochester, Minnesota
  32. Newark, New Jersey
  33. New York, New York
  34. New York, New York
  35. Durham, North Carolina
  36. Cleveland, Ohio
  37. Portland, Oregon
  38. Portland, Oregon
  39. Portland, Oregon
  40. Philadelphia, Pennsylvania
  41. Nashville, Tennessee
  42. Salt Lake City, Utah
  43. Salt Lake City, Utah
  44. Salt Lake City, Utah
  45. Ciudad Autónoma de Buenos Aires,
  46. Westmead, New South Wales
  47. Woolloongabba, Queensland
  48. Box Hill, Victoria
  49. Leuven,
  50. Rio de Janeiro, RJ
  51. Calgary, Alberta
  52. Vancouver, British Columbia
  53. Vancouver, British Columbia
  54. Toronto, Ontario
  55. Toronto, Ontario
  56. Montreal, Quebec
  57. Montreal, Quebec
  58. Brno,
  59. Praha 2,
  60. Praha 4,
  61. Marseille, Provence
  62. Creteil,
  63. Marseille,
  64. Paris,
  65. Rennes,
  66. Rennes,
  67. Toulouse,
  68. Heidelberg,
  69. Münster,
  70. Hong Kong,
  71. Hong Kong,
  72. Bologna,
  73. Firenze,
  74. Pavia,
  75. Kurume-shi, Fukuoka
  76. Kumamoto-city, Kumamoto
  77. Nagano,
  78. Groningen,
  79. Majadahonda, Madrid
  80. A Coruña,
  81. Skellefteå,
  82. Uppsala,
  83. Taipei,
  84. Taipei,
  85. Taipei,
  86. Taipei,
  87. London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Transthyretin (TTR) Amyloid CardiomyopathyVyndaqel Capsules Special Investigation (ATTR-CM)
NCT04108091
  1. Tokyo,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
Official Title  ICMJE A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)
Brief Summary This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
Detailed Description Phase 3, multicenter, global, three-arm, parallel design, placebo-controlled, double-blind, randomized study to determine efficacy, safety and tolerability of tafamidis on clinical outcomes (all-cause mortality and frequency of cardiovascular-related hospitalizations) in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention  ICMJE
  • Drug: Tafamidis
    Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
  • Drug: Tafamidis
    Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
  • Drug: Placebo
    Placebo in soft gel capsules administered once a day for 30 months
Study Arms  ICMJE
  • Experimental: Tafamidis - 20 mg
    Active Treatment-Low dose
    Intervention: Drug: Tafamidis
  • Experimental: Tafamidis - 80 mg
    Active Treatment-High Dose
    Intervention: Drug: Tafamidis
  • Placebo Comparator: Placebo
    Placebo control
    Intervention: Drug: Placebo
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 2, 2018)		441
Original Estimated Enrollment  ICMJE
 (submitted: November 20, 2013)		400
Actual Study Completion Date  ICMJE February 7, 2018
Actual Primary Completion Date February 7, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on x-ray or auscultation, peripheral edema) that required/requires treatment with a diuretic for improvement,
  • Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness > 12 mm,
  • Presence of amyloid deposits in biopsy tissue and presence of a variant TTR genotype and/or TTR precursor protein identification by immunohistochemistry, scintigraphy or mass spectrometry

Exclusion Criteria:

  • A New York Heart Association (NYHA) classification of IV.
  • Presence of primary (light chain) amyloidosis.
  • Prior liver or heart transplantation or implanted cardiac mechanical assist device.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Brazil,   Canada,   Czechia,   France,   Germany,   Italy,   Japan,   Netherlands,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01994889
Other Study ID Numbers  ICMJE B3461028
2012-002465-35 ( EudraCT Number )
ATTR-ACT ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP